EC Number   |
Inhibitors  |
Structure |
|---|
    2.6.1.19 | (+/-)-(1S,2R,4S,5S)-4-amino-6,6-difluorobicyclo[3.1.0]hexane-2-carboxylic acid |
10 mM, weak, reversible inhibitor |
   |
| 2.6.1.19 | (+/-)-(1S,2S,4S,5S)-4-amino-6,6-difluorobicyclo[3.1.0]hexane-2-carboxylic acid |
10 mM, weak, reversible inhibitor |
|
| 2.6.1.19 | (+/-)piperidine-3-sulfonic acid |
- |
|
| 2.6.1.19 | (1R,3S,4S)-3-amino-4-fluorocyclopentane-1-carboxylic acid |
mechanism-based inactivation, adduct formed is derived from enamine mechanism |
|
| 2.6.1.19 | (1R,4S)-4-amino-2-cyclopentene-1-carboxylic acid |
analogue of 4-aminobutanoate, vigabatrin |
|
| 2.6.1.19 | (1R,4S)-4-amino-3-fluorocyclopent-2-enecarboxylic acid |
weak reversible inhibition in the presence of beta-mercaptoethanol |
|
| 2.6.1.19 | (1R,4S)-4-amino-3-pentafluoroethylcyclopent-2-enecarboxylic acid |
weak reversible inhibition in the presence of beta-mercaptoethanol |
|
| 2.6.1.19 | (1R,4S)-4-amino-3-trifluoromethylcyclopent-2-enecarboxylic acid |
irreversible inhibition in the presence of beta-mercaptoethanol |
|
| 2.6.1.19 | (1S,2S,3E)-2-amino-3-(fluoromethylidene)cyclopentanecarboxylic acid |
monofluorinated analog of inhibitor CPP-115. Compound produces a metabolite that induces disruption of the Glu270-Arg445 salt bridge of GABA transaminase to accommodate interaction between the metabolite formyl group and Arg445. The inactivation mechanism is initiated by Schiff base formation with the active site pyridoxal 5'-phosphate, followed by gamma-proton removal |
|
| 2.6.1.19 | (1S,2S,3Z)-2-amino-3-(fluoromethylidene)cyclopentanecarboxylic acid |
monofluorinated analog of inhibitor CPP-115. Compound produces a metabolite that induces disruption of the Glu270-Arg445 salt bridge of GABA transaminase to accommodate interaction between the metabolite formyl group and Arg445. The inactivation mechanism is initiated by Schiff base formation with the active site pyridoxal 5'-phosphate, followed by gamma-proton removal |
|
